Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:cyclophosphamide
|
| gptkbp:activities |
microtubule stabilization
|
| gptkbp:approves |
docetaxel in 1996
paclitaxel in 1992 |
| gptkbp:can_be_used_with |
gptkb:capecitabine
gptkb:cisplatin gptkb:carboplatin gptkb:gemcitabine gptkb:trastuzumab |
| gptkbp:class |
antimicrotubule agents
|
| gptkbp:clinical_trial |
Phase IV
Phase II Phase III Phase I |
| gptkbp:developed_by |
Taxus tree
|
| gptkbp:discovered_by |
1960s
|
| gptkbp:dissolved |
soluble in organic solvents
poorly soluble in water |
| gptkbp:excretion |
urine
bile |
| gptkbp:formulation |
oral
intravenous |
| https://www.w3.org/2000/01/rdf-schema#label |
taxanes
|
| gptkbp:includes |
gptkb:docetaxel
gptkb:paclitaxel |
| gptkbp:lifespan |
approximately 11 hours
|
| gptkbp:metabolism |
liver
|
| gptkbp:research_areas |
combination therapy
oncology pharmacology chemotherapy drug resistance |
| gptkbp:side_effect |
gptkb:fandom
fatigue nausea diarrhea liver toxicity peripheral neuropathy thrombocytopenia alopecia neutropenia hypersensitivity reactions cardiotoxicity stomatitis pulmonary toxicity renal toxicity |
| gptkbp:social_structure |
C47 H51 N O14
C43 H53 N O14 S |
| gptkbp:targets |
gptkb:healthcare_organization
ovarian cancer esophageal cancer bladder cancer head and neck cancer |
| gptkbp:used_in |
gptkb:healthcare_organization
|